hero image

Biogen Issues First Progress Report of its Signature Healthy Climate, Healthy Lives™ Initiative

September 23, 2021 Company Statements

September 23, 2021 – In 2020, Biogen launched its signature Healthy Climate, Healthy Lives™ initiative, a groundbreaking $250 million, 20-year commitment to address the deeply interrelated issues of climate, health, and equity. Biogen is the first Fortune 500 company to commit to becoming fossil fuel free and established new emissions reduction targets in line with the Science Based Targets initiative, consistent with levels required to meet the goals of the Paris Agreement.

Today’s progress report details the company’s efforts to go fossil fuel free, including engagement with its employees and suppliers, and ongoing collaborations with renowned institutions to improve health – especially for vulnerable populations most impacted by climate-related events.

Biogen continues to take its role as a leader on climate and health seriously and will continue to advance this work with a sense of urgency in order to promote a world that is healthy, equitable, and sustainable for all.

To learn more and read our one-year progress report, please visit biogen.com/hchl 

thumb
December 1, 2021
Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD

In the zuranolone 50 mg cohort, the majority of patients who responded to an initial 14-day course received only one two-week course of treatment during the study and nearly 80% received only one or two treatment courses in total Zuranolone 50 mg was generally well-tolerated with an overall adverse

thumb
November 17, 2021
Update on Regulatory Review of Aducanumab in the European Union

CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) announced today an update on the ongoing review of the Marketing Authorization Application for aducanumab 100 mg/mL concentrate solution for infusion for the treatment of Alzheimer’s